ArticleEuropean heart journal2026
Atrial cardiomyopathy: markers and outcomes.
Article in European heart journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- [Atrial fibrillation screening-reading the P-wave].Innere Medizin (Heidelberg, Germany) · 2026Review
- Artificial Intelligence-Enabled Electrocardiography Model for Left Ventricular Systolic and Diastolic Dysfunction Predict Incident Atrial Fibrillation in Patients with Sinus Rhythm: A Time-Dependent Analysis.Diagnostics (Basel, Switzerland) · 2026Article
- Association of the EHRA/HRS/APHRS/LHRS definition of atrial cardiomyopathy with incident atrial fibrillation, heart failure, and stroke.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026Article
- Multiple 4q25 risk variants impair calcium homeostasis and compromise left atrial function.Cardiovascular research · 2026Article
- Residual thromboembolic risk and outcomes of oral anticoagulation discontinuation after atrial fibrillation ablation: a target trial emulation.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026Article
- Head-to-head comparison of non-invasive markers of atrial cardiomyopathy and their association with arrhythmia recurrence after atrial fibrillation ablation.Clinical research in cardiology : official journal of the German Cardiac Society · 2026Article
- Atrial Fibrillation in Infiltrative Cardiomyopathies: From Atrial Cardiomyopathy Imaging to Targeted Management-A Narrative Review.Medicina (Kaunas, Lithuania) · 2026Review
- Prevalence of deleterious variants in cardiomyopathy genes in early-onset atrial fibrillation.European journal of human genetics : EJHG · 2026Article
- Echocardiographic strain imaging and progression of atrial fibrillation in low-risk individuals.International journal of cardiology. Heart & vasculature · 2026Article
- Role of imaging techniques in monitoring atrial cardiomyopathy and atrial failure: a scientific statement.ESC heart failure · 2026Review
- Atrial Cardiomyopathy.Maedica · 2026Article
- Case Report: Right-atrial reverse remodeling causing resolution of new-onset torrential tricuspid regurgitation after successful rhythm control.Frontiers in cardiovascular medicine · 2026Article
- Atrial volumetrics and recurrence after catheter ablation for atrial fibrillation.Frontiers in cardiovascular medicine · 2026Article
- Renal Function, Atrial Cardiopathy, and Their Joint Association with Mortality in the General Population.Journal of clinical medicine · 2025Article
- Atrial Dilated Cardiomyopathy: From Molecular Pathogenesis to Clinical Implications.Journal of clinical medicine · 2025Review
- The present and future of antiarrhythmic drugs.JRSM cardiovascular diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
BACKGROUND AND
aimsAtrial cardiomyopathy (AtCM) is increasingly recognized as an important substrate for atrial fibrillation (AF). This study aimed to examine potential markers and risk factors of AtCM, and associations with incident AF, heart failure (HF), and stroke.
methodsIndividuals from the UK Biobank with cardiac magnetic resonance imaging and electrocardiographic information were included. Atrial cardiomyopathy markers included left atrial dilation, left atrial mechanical dysfunction, P-wave prolongation, and abnormal P-wave terminal force. Risk factors for AtCM were assessed using logistic regressions. Incident AF, HF, and stroke according to AtCM markers were assessed in multivariable Cox-regression and cumulative incidence models. AF risk according to AtCM markers, clinical and genetic risk factors was evaluated by integrating the HARMS2-AF score and a polygenic risk score for AF. We used net reclassification improvement (NRI) to evaluate reclassification of risk when considering AtCM markers.
resultsAmong 26 467 individuals, 4145 (15.7%) had ≥1 marker and 619 (2.3%) had ≥2 markers of AtCM. Age, coronary artery disease, and hypertension were consistently associated with AtCM. Having one AtCM marker conferred a hazard ratio (HR) for AF of 1.88 [95% confidence interval (CI): 1.54-2.31; P < .001], with higher rates observed in individuals with ≥2 markers (HR: 4.59; 95% CI: 3.52-5.99; P < .001). Addition of AtCM markers was associated with an NRI of 13.7% (95% CI: 9.2%-18.3%). Integration of clinical and genetic risk factors indicated an additive effect on AF rates. Having ≥2 markers associated with HF (HR: 3.08, 95% CI: 2.03-4.66, P < .001), and stroke (HR: 3.07, 95% CI: 1.78-5.28, P < .001).
conclusionsOne in seven individuals had at least one marker of AtCM. Atrial cardiomyopathy markers were associated with AF, HF, and stroke, supporting AtCM as a common substrate for all three outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.